PCCTC investigator Andrew Armstrong (Duke Cancer) discusses the current treatment landscape for metastatic prostate cancer

WATCH: Scott Tagawa sat down with OncoDaily at #ASCO24 to speak about #research he led on 177Lu-PSMA-617 for advanced #ProstateCancer bit.ly/3xgBEvP

Excited to share results from our successful phase 2 The PCCTC trial STARTAR: salvage RT w/ chemohormonal triple tx in high risk PSA relapse post RP. Phase 3 next! sciencedirect.com/science/articl… European Urology Oncology Tian Zhang, MD, MHS Dan George DCI Center for Prostate & Urologic Cancers Scott Tagawa Wake Forest University School of Medicine

Join us for an informative session where Dr. Alicia Morgans, Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute, will discuss Prostate Cancer Androgen Deprivation Therapy (ADT), what it is, and how and when treatment classes… dlvr.it/T9KwVb

PCCTC Medical Director Michael Morris (Memorial Sloan Kettering Cancer Center) and PCCTC investigator Dan George (Duke Cancer) discuss the radioligand landscape for prostate cancer with UroToday.com

We are thrilled to announce a monumental new collaboration with American Cancer Society and Trial Library to support a national initiative to accelerate the recruitment of Black patients to #ProstateCancer clinical trials. Full press release: pressroom.cancer.org/releases?item=…

Exciting work ahead to get more Black men on clinical trials for prostate cancer. Looking forward to seeing what Trial Library, The PCCTC, and American Cancer Society can do together!

Congratulations! The PCCTC-managed phase 3 prostate cancer DORATrial is now open at all sites in Spain and 64 sites globally!

PCCTC Medical Director Michael Morris discusses optimal imaging standards for advanced #prostatecancer with Alicia Morgans, MD, MPH via UroToday.com

The PCCTC-managed study of the novel multi-target tyrosine kinase inhibitor tinengotinib in combination with standard treatments in people with #prostatecancer has enrolled its first participants. For more information on the phase 1b/2 trial visit clinicaltrials.gov/study/NCT06457…

Results from the PCCTC-managed Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) study led by Dr Maha Hussain (Northwestern Feinberg School of Medicine) published in Clinical Cancer Research: aacrjournals.org/clincancerres/…

BRCAaway: Most compelling study suggesting that combined Abi+Olap is better than sequential Abi→Olap or Olap→Abi for BRCA/ATM-altered 1st-line mCRPC. Congrats to Maha Hussain, The PCCTC, Neeraj Agarwal, MD, FASCO, Arul Chinnaiyan, Zachery Reichert, Leonidas Platanias, MD doi.org/10.1158/1078-0…

Congrats to Maha Hussain and Emmanuel Antonarakis and the rest of the team and The PCCTC. This study is the first study to compare the three arms, Abi vs Olap vs Abi/Olap in the first-line CRPC setting. However, many patients will have seen abi or other ARPI in HSPC setting. 1/2

Huge congrats to Cathy Handy Marshall, MD MPH and Benjamin Teply for this paradigm-breaking study. In BCR prostate cancer, Olaparib shows profound activity (w/out ADT!) in HRRm+ pts, esp. in BRCA2+ pts (100% response rate). The PCCTC Johns Hopkins Kimmel Cancer Center @umncancer jamanetwork.com/journals/jamao…

Emmanuel Antonarakis Cathy Handy Marshall, MD MPH Benjamin Teply The PCCTC Johns Hopkins Kimmel Cancer Center Masonic Cancer Center, University of Minnesota Just in JAMA Oncology 👉Congrats Cathy Handy Marshall, MD MPH Benjamin Teply & team for showing efficacy of olaparib monotherapy (without ADT) in HRRm+ BCR #prostatecancer Love the ADT sparing approach. Kudos to the super mentor Emmanuel Antonarakis . PCF Science UroToday.com OncoAlert

Now hiring! Join our team as a Research Biostatistician; we’re looking for a dynamic professional to support statistical activities across all phases of clinical development and enhance the data modeling workflows of our Data Science Team. Learn more: careers.mskcc.org/vacancies/2024…

The PCCTC receives gift from Friends and Family Against Prostate Cancer to support innovative enhancements to multicenter prostate cancer clinical research. Full press release: pcctc.org/news/the-prost…

The PCCTC-managed phase 3 study of radium-223 with docetaxel in patients with prostate cancer has now been activated at 67 sites across the globe.

Congrats to Dan George on this publication on the retrospective analysis of daro vs enza vs apa in nmCRPC, showing better tolerability and efficacy of daro over other two. ARIs in Patients With Nonmetastatic Castration-Resistant Prostate Cancer jamanetwork.com/journals/jaman…

Pleased to share our recent European Urology manuscript on post treatment PSA declines and patient survival and long term outcomes after 177Lu-PSMA-617 therapy from the VISION trial! DCI Center for Prostate & Urologic Cancers Michael Morris Novartis Cancer Duke Cancer sciencedirect.com/science/articl…